-
Exondys Sales, Takeover Speculation Fuel Sarepta Therapeutics
Friday, April 28, 2017 - 11:31am | 380Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are up more than 6.5 percent Friday after the company reported first-quarter net revenue from EXONDYS 51 of $16.3 million and guided for $95 million in revenue for the full year, up from previous guidance of $80 million. In addition to the revenue beat...
-
The Unlikely Story Of How Amicus Therapeutics Came To Be
Thursday, March 2, 2017 - 2:31pm | 583Read More...Many Americans who watched President Donald Trump’s address to Congress this week were left curious about the story of Megan Crowley and her father John Crowley. Trump made a point to use the Crowley’s story as an example of the type of entrepreneurial spirit the government needs to...
-
Carl Icahn's Track Record In Big Pharma
Friday, February 24, 2017 - 10:40am | 1192Read More...Billionaire investor and corporate raider Carl Icahn has trained his eyes on Bristol-Myers Squibb Co (NYSE: BMY). A Wall Street Journal report revealed on Tuesday that Icahn has picked up a substantial stake in the pharma giant, although the report did not put a number to it. Does Icahn's...
-
Sanofi Is Looking For Rare Disease Acquisitions, FT Says
Monday, February 29, 2016 - 10:21am | 220Read More...Sanofi SA (ADR) (NYSE: SNY) is actively looking to enter the rare disease drugs segment through an acquisition. The Financial Times reported on Sunday that David Meeker, head of Sanofi's Genzyme specialty care business, suggested that rare disease assets represent potential targets as the...
-
Wedbush Likes Voyager's Gene Therapy Pipeline, Initiates At Outperform
Monday, December 7, 2015 - 10:21am | 393Read More...Shares of Voyager Therapeutics Inc (NASDAQ: VYGR) have appreciated 64.79 percent over the past month, with the share price almost at the 52-week high on December 4. Wedbush’s David M. Nierengarten initiated coverage of the company with an Outperform rating and price target of $36. The...
-
Market Wrap For May 30: 'Sell In May And Go Away' Proves To Be Bad Advice
Friday, May 30, 2014 - 4:30pm | 1763Read More...U.S. stocks were mostly higher on the final trading day of May, as both the S&P 500 and Dow indices close at record highs, despite disappointing consumer spending data reported on Friday morning. Loretta Mester, the soon to be Cleveland Fed President argued in a speech the importance of...
-
Oppenheimer's Current Biotech Ratings
Monday, September 13, 2010 - 10:41am | 138Read More...Stock Prices as of September 10, 2010 Anadys Pharmaceuticals Inc. (NASDAQ: ANDS) $1.75, PERFORM BioMarin Pharmaceutical (NASDAQ: BMRN) $22.62, PERFORM Chelsea Therapeutics (NASDAQ: CHTP) $3.91, PERFORM Dynavax Technologies (NASDAQ: DVAX) $1.69, PERFORM Genzyme (NASDAQ: GENZ) $70.63, PERFORM...
-
_0.jpg)
Genzyme Options Pricing In More Upside (GENZ)
Wednesday, September 1, 2010 - 4:44pm | 179Read More...Shares of Genzyme (NASDAQ: GENZ) were on the move again today up 27c to settle at 70.38 on volume of 4.7 million shares a hair over average. The board of Genzyme revealed they are open tp a merger with Sanofi-aventis (NYSE: SNY) though are looking for a price greater than $69 a share. Today...
-
.jpg)
Aventis Bid For Genzyme $18.5Bil All Cash (GENZ)
Sunday, August 29, 2010 - 3:49pm | 235Read More...This Sunday morning French pharmaceutical company Aventis, revealed their official bid for Genzyme, (NASDAQ: GENZ). Looks like merger Monday will be living up to it's nick name tomorrow with this 38% premium bid. The 38% premium represents the move from the low 50$ level when the takeover...
